ATE321556T1 - Behandlung gastrointestinaler stroma-tumoren - Google Patents

Behandlung gastrointestinaler stroma-tumoren

Info

Publication number
ATE321556T1
ATE321556T1 AT01988712T AT01988712T ATE321556T1 AT E321556 T1 ATE321556 T1 AT E321556T1 AT 01988712 T AT01988712 T AT 01988712T AT 01988712 T AT01988712 T AT 01988712T AT E321556 T1 ATE321556 T1 AT E321556T1
Authority
AT
Austria
Prior art keywords
treatment
gastrointestinal stroma
tumors
stroma tumors
gastrointestinal
Prior art date
Application number
AT01988712T
Other languages
English (en)
Inventor
Elisabeth Buchdunger
Renaud Capdeville
George Daniel Demetri
Sasa Dimitrijevic
Brian J Druker
Jonathan A Fletcher
Heikki Joensuu
P O Box Haartmaninkatu
Sandra Leta Silberman
David Tuveson
Michael C Heinrich
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22920224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE321556(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE321556T1 publication Critical patent/ATE321556T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Farming Of Fish And Shellfish (AREA)
AT01988712T 2000-10-27 2001-10-26 Behandlung gastrointestinaler stroma-tumoren ATE321556T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24381000P 2000-10-27 2000-10-27

Publications (1)

Publication Number Publication Date
ATE321556T1 true ATE321556T1 (de) 2006-04-15

Family

ID=22920224

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01988712T ATE321556T1 (de) 2000-10-27 2001-10-26 Behandlung gastrointestinaler stroma-tumoren

Country Status (25)

Country Link
US (1) US6958335B2 (de)
EP (1) EP1332137B1 (de)
JP (1) JP4386635B2 (de)
KR (1) KR100885129B1 (de)
CN (1) CN1276754C (de)
AT (1) ATE321556T1 (de)
AU (2) AU1826202A (de)
BR (1) BRPI0114870B8 (de)
CA (1) CA2424470C (de)
CY (1) CY1105055T1 (de)
CZ (1) CZ303944B6 (de)
DE (1) DE60118430T2 (de)
DK (1) DK1332137T3 (de)
ES (1) ES2260317T3 (de)
HU (1) HU229106B1 (de)
IL (2) IL155029A0 (de)
MX (1) MXPA03003703A (de)
NO (1) NO324948B1 (de)
NZ (1) NZ525254A (de)
PL (1) PL209733B1 (de)
PT (1) PT1332137E (de)
RU (1) RU2301066C2 (de)
SK (1) SK287335B6 (de)
WO (1) WO2002034727A2 (de)
ZA (1) ZA200302155B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
KR20080091866A (ko) * 2001-05-16 2008-10-14 노파르티스 아게 Ν-｛5-[4-(4-메틸-피페라지노-메틸)-벤조일아미도]-2-메틸페닐｝-4-(3-피리딜)-2-피리미딘-아민 및 화학치료제를 포함하는 배합물
JP2005500041A (ja) * 2001-06-29 2005-01-06 アブ サイエンス 強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
WO2003002108A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
CA2452366A1 (en) * 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
US7678805B2 (en) * 2001-06-29 2010-03-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
CA2452371A1 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
CA2461182A1 (en) * 2001-09-20 2003-05-01 Ab Science Use of tyrosine kinase inhibitors for promoting hair growth
US20040242601A1 (en) * 2001-09-20 2004-12-02 Alain Moussy Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
EP1478380B1 (de) * 2002-02-27 2006-08-02 AB Science Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
CN100467064C (zh) * 2003-09-19 2009-03-11 诺瓦提斯公司 伊马替尼和米哚妥林在制备治疗胃肠道基质肿瘤药物中的应用
WO2007089716A2 (en) * 2006-02-01 2007-08-09 The Regents Of The University Of California Use of aminopyrimidine compounds in the treatment of immune disorders
CN101534831B (zh) * 2006-09-11 2013-07-17 柯瑞斯公司 包含锌结合基团的取代的酪氨酸抑制剂
CA2662937A1 (en) * 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20090082361A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched imatinib
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
WO2010120386A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
AU2012225693A1 (en) 2011-03-04 2013-09-19 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
SG11201405099UA (en) 2012-02-21 2014-10-30 Ranbaxy Lab Ltd Stable dosage forms of imatinib mesylate
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP2877159B8 (de) 2012-07-27 2018-02-14 Izumi Technology, LLC. Efflux-inhibitorzusammensetzungen und behandlungsverfahren damit
CA2919498C (en) 2013-07-31 2023-07-25 Windward Pharma, Inc. Aerosol nintedanib compounds and uses thereof
US11285152B2 (en) 2017-07-20 2022-03-29 Kashiv Biosciences, Llc Stable oral pharmaceutical composition of imatinib
EA202091763A1 (ru) 2018-01-31 2020-12-14 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Комбинированная терапия для лечения мастоцитоза
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
EP3938363A1 (de) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Festkörperformen von ripretinib
AU2020326612B2 (en) 2019-08-02 2025-10-23 Onehealthcompany, Inc. Treatment of canine cancers
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
JP7818502B2 (ja) 2019-08-12 2026-02-20 デシフェラ・ファーマシューティカルズ，エルエルシー 胃腸間質腫瘍を治療するためのリプレチニブ
AU2020417282B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
SI4084778T1 (sl) 2019-12-30 2024-01-31 Deciphera Pharmaceuticals, Llc Formulacije inhibitorja amorfne kinaze in načini njihove uporabe
KR102535840B1 (ko) 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1528449A1 (ru) * 1985-06-05 1989-12-15 Центральный институт усовершенствования врачей Способ релаксации илеоцекального отдела кишечника
TW225528B (de) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JP2002523455A (ja) * 1998-08-31 2002-07-30 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての幾何学的に制限された２−インドリノン誘導体

Also Published As

Publication number Publication date
HU229106B1 (en) 2013-07-29
PL362148A1 (en) 2004-10-18
EP1332137A2 (de) 2003-08-06
MXPA03003703A (es) 2005-01-25
IL155029A (en) 2009-09-22
PL209733B1 (pl) 2011-10-31
HUP0301512A2 (hu) 2003-11-28
JP4386635B2 (ja) 2009-12-16
DK1332137T3 (da) 2006-07-17
ES2260317T3 (es) 2006-11-01
KR20030051656A (ko) 2003-06-25
AU2002218262B2 (en) 2005-09-29
NO324948B1 (no) 2008-01-07
AU1826202A (en) 2002-05-06
ZA200302155B (en) 2004-04-22
SK287335B6 (sk) 2010-07-07
PT1332137E (pt) 2006-07-31
US6958335B2 (en) 2005-10-25
CN1622808A (zh) 2005-06-01
NO20031833L (no) 2003-04-24
JP2004512328A (ja) 2004-04-22
DE60118430D1 (de) 2006-05-18
BRPI0114870B1 (pt) 2020-06-16
RU2301066C2 (ru) 2007-06-20
NZ525254A (en) 2006-02-24
IL155029A0 (en) 2003-10-31
CY1105055T1 (el) 2010-03-03
CZ20031152A3 (en) 2004-04-14
BR0114870A (pt) 2004-02-17
HK1058193A1 (en) 2004-05-07
BRPI0114870B8 (pt) 2021-05-25
CZ303944B6 (cs) 2013-07-10
US20040023976A1 (en) 2004-02-05
CA2424470A1 (en) 2002-05-02
CN1276754C (zh) 2006-09-27
DE60118430T2 (de) 2006-10-26
NO20031833D0 (no) 2003-04-24
WO2002034727A3 (en) 2003-03-27
KR100885129B1 (ko) 2009-02-23
WO2002034727A2 (en) 2002-05-02
CA2424470C (en) 2009-06-09
SK5182003A3 (en) 2004-02-03
EP1332137B1 (de) 2006-03-29

Similar Documents

Publication Publication Date Title
DE60118430D1 (de) Behandlung gastrointestinaler stroma-tumoren
TR200000060T2 (tr) Bir N-fenil-2-pirimidinamin türevinin kristal modifikasyonu ve yapım işlemleri ve kullanımı.
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
ATE399555T1 (de) Behandlung der rheumatoiden arthritis mit imitanib
ATE468855T1 (de) Kombination von stickstoff-senf analogen und imatinib für die behandlung von chronischer lymphatischer leukämie
AU2003216621A8 (en) Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
BR0312242A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida para o tratamento da fibrose pulmonar
AU2003209521A1 (en) Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas
WO2004103374A3 (en) Imatinib combinations for head and neck cancers
TNSN05304A1 (en) Use of tyrosine kinase inhibitor to treat diabetes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1332137

Country of ref document: EP